Holen Sie sich die Stockscreener-App
0.2848
5.45%
0.0169
Schlusskurs vom Vortag:
$0.2679
Offen:
$0.2787
24-Stunden-Volumen:
324.43K
Relative Volume:
0.04
Marktkapitalisierung:
$993.15K
Einnahmen:
$54,200
Nettoeinkommen (Verlust:
$-22.30M
KGV:
-0.0241
EPS:
-11.793
Netto-Cashflow:
$-12.98M
1W Leistung:
-21.72%
1M Leistung:
-54.44%
6M Leistung:
-92.99%
1J Leistung:
-96.89%
1-Tages-Spanne:
$0.27
$0.288
1-Wochen-Bereich:
$0.25
$0.3739
52-Wochen-Spanne:
$0.25
$17.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Firmenname
Hcw Biologics Inc
Sektor
Branche
Telefon
954-842-2024
Adresse
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
0.2824 | 942.15K | 54,200 | -22.30M | -12.98M | -11.79 |
VRTX
Vertex Pharmaceuticals Inc
|
433.63 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.48 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.68 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.95 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.56 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Hcw Biologics Inc Aktie (HCWB) Neueste Nachrichten
Growth Recap: Will HCW Biologics Inc outperform tech stocksEarnings Risk Report & Expert Verified Stock Movement Alerts - baoquankhu1.vn
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - The Manila Times
HCW Biologics Q4 revenue drops sharply on license suspension - TradingView
HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
HCW Biologics (NASDAQ: HCWB) outlines immunotherapy pipeline, deals and IP - Stock Titan
HCW Biologics (NASDAQ: HCWB) 2025 loss, going concern and Nasdaq risk - Stock Titan
Hair-loss trial starts as HCW Biologics warns on funding runway - Stock Titan
HCW Biologics Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Growth Value: Is HCW Biologics Inc gaining market shareDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn
HCWB Should I Buy - Intellectia AI
HCWB (HCW Biologics) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
HCWB Technical Analysis & Stock Price Forecast - Intellectia AI
Forecast Cut: Will HCW Biologics Inc benefit from green energy policiesWeekly Stock Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
HCW Biologics highlights positive findings for CAR-T therapy manufacturing - MSN
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday - Defense World
If You Invested $1,000 in Hcw Biologics Inc. (HCWB) - Stock Titan
HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN
HCW Biologics receives $7M upfront fee from China licensee By Investing.com - Investing.com South Africa
HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 - Minichart
HCW Biologics Secures $7M License Deal for HCW11-006 - TipRanks
HCW Biologics Closes Exclusive Global License for HCW11-006, Receives Upfront Payment - TradingView
HCW Biologics receives $7M upfront fee from China licensee - Investing.com
[8-K] HCW Biologics Inc. Reports Material Event - Stock Titan
HCW Biologics Inc. Receives $7 Million Upfront License Fee from Beijing Trimmune Biotech for HCW11-006 Development and Commercialization Rights - Quiver Quantitative
Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic - TradingView
New fusion immunotherapy deal brings HCW Biologics $7M upfront - Stock Titan
HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume - Meyka
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - Investing News Network
Small Cap Stocks To Keep An Eye OnMarch 16th - MarketBeat
HCW Biologics Inc. (HCWB) Stock: Science Advances Study Highlights Next-Gen CAR-T Manufacturing Strategy - parameter.io
HCW Biologics’ compound shows promise in CAR-T cell production By Investing.com - Investing.com Canada
Promising Pharmaceutical Stocks To Keep An Eye OnMarch 16th - MarketBeat
Trading Volume Surges in Biotech, Tech, and Energy Stocks | Market RecapNews and Statistics - IndexBox
HCW Biologics (HCWB) spikes 71% as micro-cap volatility returns after Nasdaq compliance and recent financing - Quiver Quantitative
HCW Biologics announces positive research results for CAR-T cell therapy - TipRanks
HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy - Asianet Newsable
HCW Biologics’ compound shows promise in CAR-T cell production - Investing.com
HCW Biologics reports positive CAR-T cell therapy research results By Investing.com - Investing.com Australia
HCW Biologics Announces Positive Research Results for CAR-T - GlobeNewswire
HCW Biologics (NASDAQ: HCWB) seeks approval for large warrant issuances and deep repricing - Stock Titan
HCW Biologics restructures obligations to regain Nasdaq compliance - MSN
Hedge Fund Moves: What is HCW Biologics Incs revenue forecastLayoff News & Low Risk Entry Point Tips - baoquankhu1.vn
AI Stocks: Will HCW Biologics Inc outperform tech stocksTrade Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
Buyout Rumor: Can HCW Biologics Inc stock double in the next yearWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
AI Stocks: Is HCW Biologics Inc forming a breakout patternWeekly Gains Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
HCWB Earnings History & Surprises | EPS & Revenue Results | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics (NASDAQ: HCWB) seeks warrant approvals at Apr 27 meeting - Stock Titan
HCWB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight - The Globe and Mail
HCW Biologics regains compliance with all continued listing rules for Nasdaq per Nasdaq determination letter - marketscreener.com
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - The Manila Times
Finanzdaten der Hcw Biologics Inc-Aktie (HCWB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hcw Biologics Inc-Aktie (HCWB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Winer Gary M | Director |
May 16 '25 |
Buy |
7.45 |
1,342 |
9,998 |
4,075 |
| GARRETT SCOTT T | Director |
May 16 '25 |
Buy |
7.45 |
13,423 |
100,001 |
25,505 |
| Winer Gary M | Director |
May 08 '25 |
Buy |
26.00 |
2,308 |
60,008 |
2,733 |
| Wong Hing C | Chief Executive Officer |
May 08 '25 |
Buy |
26.00 |
92,500 |
2,405,000 |
493,857 |
| GARRETT SCOTT T | Director |
May 08 '25 |
Buy |
26.00 |
5,385 |
140,010 |
12,082 |
| Byam Rebecca | Chief Financial Officer |
May 08 '25 |
Buy |
26.00 |
8,462 |
220,012 |
43,010 |
| Flowers Lee | SVP of Business Development |
May 08 '25 |
Buy |
26.00 |
962 |
25,012 |
5,720 |
| Greene Rick S. | Director |
May 08 '25 |
Buy |
26.00 |
962 |
25,012 |
2,066 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):